Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio ViewXTAE:BIOV 41 Buyback Yield % is -19.01 as of Sep. 14, 2026. GuruFocus rates XTAE:BIOV with a GF Score™ of 41/100 and a GF Value™ of ₪1.70 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Bio View ranks worse than 76.45% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Bio View's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:BIOV vs ABT, SYK, MDT: Buyback Yield % Comparison
For the Medical Devices subindustry, Bio View's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio View Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio View's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Bio View's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio View (XTAE:BIOV) has a Buyback Yield % of -19.01 as of Sep. 14, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bio View and its competitors. According to the industry distribution chart, Bio View ranks #250 out of 327 companies in the Medical Devices & Instruments industry, placing it in the top 76.5%.
Is Bio View's Buyback Yield % too high?
Bio View's current Buyback Yield % is -19.01. Based on the distribution chart, Bio View ranks #250 out of 327 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bio View has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio View's Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bio View ranks #250 out of 327 companies for Buyback Yield %. This places Bio View in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bio View and its competitors. Bio View's current Buyback Yield % is -19.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio View stock overvalued right now?
Based on GuruFocus' analysis, Bio View (XTAE:BIOV) is currently considered Possible Value Trap. The stock's GF Value™ is ₪1.70, compared to a current price of ₪0.81 — trading 52.6% below its estimated fair value. The current Buyback Yield % is -19.01. Bio View's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Bio View (XTAE:BIOV), the current Buyback Yield % is -19.01 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio View (XTAE:BIOV) Overvalued in 2026?
Based on GuruFocus' analysis, Bio View stock appears to be undervalued.
The current stock price of ₪0.81 is trading 52.6% below its estimated GF Value™ of ₪1.70.
GuruFocus considers Bio View to be Possible Value Trap.
Key valuation signals for XTAE:BIOV:
Buyback Yield %: -19.01
GF Value™: ₪1.70 vs. price of ₪0.81 (52.6% below fair value)
No single metric tells the full story. See the XTAE:BIOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.
41GF Score
Get the complete analysis for XTAE:BIOV
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:BIOV has been successfully added to your 
